Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1) , 80-88
- https://doi.org/10.1080/10428190600886164
Abstract
Application of five-color staining may improve quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. We analysed bone marrow samples in 139 cases using a comprehensive antibody panel with five-color combinations. Sensitivity was estimated by quantification of leukemia-associated aberrant immunophenotype (LAIP)-positive cells for each LAIP in 18 normal bone marrow (BM) samples. The logarithmic difference (LD) in LAIP-positive cells between leukemic and normal BM amounted to a median of 3.32 (range 1.76 – 4.89). Skipping one color resulted in an increase of LAIP-positive normal bone marrow cells while percentages of LAIP-positive leukemic cells changed only marginally (median gain in LD = 0.54; maximum gain = 3.30). Because regenerating bone marrow has not been used as control data are most important to post-therapy checkpoints. In 32 patients with clinical follow-up, a LD higher than the median (3.25) at the follow-up checkpoint corresponded to a longer event-free survival. These data suggest that the application of five-color staining significantly improves the sensitivity and accuracy of the method.Keywords
This publication has 33 references indexed in Scilit:
- Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaBlood, 2004
- MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemiaLeukemia, 2004
- FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid LeukaemiaActa Haematologica, 2004
- New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsBlood, 2003
- Determination of minimal residual disease in leukaemia patientsBritish Journal of Haematology, 2003
- Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cellsLeukemia, 2003
- Detection of minimal residual disease in acute myeloid leukemiaCurrent Oncology Reports, 2002
- Minimal residual disease evaluation in acute myeloid leukaemiaThe Lancet, 2002
- Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable stateBlood, 2002
- Dependence of age-specific incidence of acute myeloid leukemia on karyotypeBlood, 2001